Acroscell Launches 3D Cardiotoxicity Testing to Accelerate the Development of New Drug Candidates

Acroscell announced the release of 3D cardiotoxicity testing to support the procedure for accelerating new drug candidates into the market.

New York, USA – July 30, 2021 – Acroscell, the professional electrophysiology of Creative Bioarray, is a global leading platform focused on research and development including cardiac & neuronal safety profiling and translational assays for the academia, pharmaceutical, and biotechnology industries. As an ideal and reliable innovation partner in research endeavors, Acroscell announced the release of 3D cardiotoxicity testing to support the procedure for accelerating new drug candidates into the market.

In order to overcome the weaknesses and limitations of current cell-based and animal-based tests, a 3D model with appropriate biophysical tissue structure is generated for cardiotoxicity testing in order to provide highly predictive and detailed information for human in vivo research. The 3D structure of the Acroscell heart cell model is more representative of the tissues in the body than the traditional monolayer cell culture. Meanwhile, it can provide a variety of 3D culture physiological model systems made of cell lines, human iPS cells and ES cells for customers to choose from, and covering most of the test endpoints of the cardiotoxicity test.

Acroscell tests target compounds at a series of concentrations, focusing on a wide range of test endpoints, including QT interval, pulsation rate change, contraction rate and duration, and the compound’s effect on different ion channels, enabling customers to better characterize the target compound. For professional services in cardiac electrophysiology, in addition to 3D cardiotoxicity testing, Acroscell also provides services including cardiac bioassays and cardiac ion channel screen panels.

Acroscell provides a variety of research endpoints, and can generate high-quality, reproducible data according to the requirements of the research plan. All test models are analyzed in a dose-dependent manner with approved benchmark positive controls. Acroscell’s solutions include screening study design for preliminary safety assessment, ECG/MAP/LVP, coronary blood flow/pressure, MAP duration, QT and QRS duration, LVDP, MAP triangulation (instability), frequency dependence and recovery, effective refractory period. Whether customers are trying to evaluate potential cardiovascular problems during the pilot optimization process or trying to verify in vivo efficacy, Acroscell can provide high-quality and repeatable results to advance drug discovery programs.

“Each of our technical directors focuses on selected research areas, so they will provide you with professional scientific support. They are involved in all processes, including consulting with you to determine the appropriate model to meet the scientific goals.” said Hannah Cole, the marketing director of Acroscell, she also added, “For customers who have any special needs for 3D cardiotoxicity services, we can customize services according to your needs.”

About Acroscell

As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-386-8241
Country: United States